Get the Stockscreener App
5.48
4.41%
-0.24
Cytomx Therapeutics Inc stock is traded at $5.48, with a volume of 1.32M.
It is down -4.41% in the last 24 hours and up +30.19% over the past month.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
See More
Previous Close:
$5.72
Open:
$5.69
24h Volume:
1.32M
Relative Volume:
0.42
Market Cap:
$927.66M
Revenue:
$101.21M
Net Income/Loss:
$-569.00K
P/E Ratio:
-274.00
EPS:
-0.02
Net Cash Flow:
$-56.88M
1W Performance:
+1.44%
1M Performance:
+30.19%
6M Performance:
+125.01%
1Y Performance:
+530.08%
1-Day Range:
$5.40
$5.7001
1-Week Range:
$5.04
$6.15
52-Week Range:
$0.40
$6.15
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Name
Cytomx Therapeutics Inc
Sector
Industry
Phone
650.515.3185
Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
5.475 | 969.17M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.83 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-20-26 | Initiated | Guggenheim | Buy |
| Sep-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jul-31-25 | Initiated | Oppenheimer | Outperform |
| May-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| May-28-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-09-24 | Upgrade | Wedbush | Neutral → Outperform |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Apr-22-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-14-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-07-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-07-22 | Downgrade | Mizuho | Buy → Neutral |
| Jul-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-18-22 | Upgrade | Barclays | Underweight → Overweight |
| Nov-15-21 | Initiated | BTIG Research | Buy |
| May-28-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-29-21 | Initiated | JP Morgan | Overweight |
| Mar-23-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-22-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-20 | Downgrade | Jefferies | Buy → Hold |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-24-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Nov-11-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-13-19 | Initiated | Mizuho | Buy |
| May-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Nov-26-18 | Initiated | Piper Jaffray | Overweight |
| Oct-15-18 | Initiated | Goldman | Neutral |
| Sep-13-18 | Initiated | H.C. Wainwright | Buy |
| Jun-01-18 | Initiated | SunTrust | Buy |
| Jan-05-18 | Initiated | Citigroup | Buy |
| Sep-08-17 | Initiated | Wedbush | Outperform |
| Mar-27-17 | Initiated | H.C. Wainwright | Buy |
| Mar-02-17 | Initiated | Instinet | Buy |
| Jan-03-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-02-15 | Initiated | Oppenheimer | Outperform |
View All
Cytomx Therapeutics Inc Stock (CTMX) Latest News
Is CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - simplywall.st
Panic Selling: What hedge funds are buying CytomX Therapeutics IncJuly 2025 Institutional & Risk Managed Investment Entry Signals - baoquankhu1.vn
CytomX Therapeutics (NASDAQ:CTMX) Sets New 1-Year HighShould You Buy? - MarketBeat
Patterns Watch: Is CytomX Therapeutics Inc benefiting from interest rate changesJuly 2025 Momentum & AI Driven Stock Price Forecasts - baoquankhu1.vn
CytomX Therapeutics (NASDAQ:CTMX) Shares Down 5.3%Here's Why - MarketBeat
Guggenheim Upgrades CytomX Therapeutics (NASDAQ:CTMX) to "Strong-Buy" - MarketBeat
CytomX stock rises 31% in a month: Here's what you should know - MSN
Piper Sandler raises CytomX Therapeutics stock price target to $10 on cancer drug data - Investing.com Canada
CTMX: Barclays Raises Price Target from $6.00 to $8.00, Maintains Overweight Rating | CTMX Stock News - GuruFocus
Guggenheim Initiates Coverage of CytomX Therapeutics (CTMX) with Buy Recommendation - Nasdaq
Guggenheim Initiates Coverage on CytomX Therapeutics (CTMX) with 'Buy' Rating | CTMX Stock News - GuruFocus
CytomX Therapeutics (CTMX) Receives Target Price Upgrade from Pi - GuruFocus
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Formidable Asset Management LLC Sells 194,513 Shares of CytomX Therapeutics, Inc. $CTMX - MarketBeat
CytomX Stock Rises 31% in a Month: Here's What You Should Know - Yahoo Finance
Risk Analysis: What is LILAKs book value per shareGDP Growth & AI Powered Trade Plan Recommendations - baoquankhu1.vn
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected - 富途资讯
CytomX Therapeutics (NASDAQ:CTMX) Reaches New 12-Month HighHere's What Happened - MarketBeat
CytomX Therapeutics' (NASDAQ:CTMX) investors will be pleased with their incredible 402% return over the last year - Yahoo Finance
CTMX Stock Price, Forecast & Analysis | CYTOMX THERAPEUTICS INC (NASDAQ:CTMX) - Chartmill
Volatility Watch: Does CytomX Therapeutics Inc have strong EBITDA margins2025 Trading Volume Trends & Weekly Watchlist of Top Performers - baoquankhu1.vn
Is CytomX Therapeutics Inc stock heavily shortedEarnings Overview Summary & Verified Short-Term Plans - baoquankhu1.vn
Drugmaker signed East Bay's biggest Q4 lease, moving away from South San Francisco - The Business Journals
Bull Run: Is CytomX Therapeutics Inc. stock a top pick in earnings seasonJobs Report & Reliable Price Breakout Alerts - Bộ Nội Vụ
Guidance Update: What hedge funds are buying CytomX Therapeutics Inc2025 AllTime Highs & Verified Technical Trade Signals - baoquankhu1.vn
Swing Trade: Will CytomX Therapeutics Inc stock recover faster than market2025 Buyback Activity & Real-Time Buy Zone Alerts - Bộ Nội Vụ
Breakout Zone: Is CytomX Therapeutics Inc. stock gaining market shareJuly 2025 Action & Weekly Setup with ROI Potential - Улправда
Gainers Report: Will CytomX Therapeutics Inc stock recover faster than marketWeekly Volume Report & Free Technical Pattern Based Buy Signals - Bộ Nội Vụ
Is CytomX Therapeutics Inc. stock dividend yield sustainableJuly 2025 Decliners & Real-Time Volume Analysis Alerts - Улправда
Is CytomX Therapeutics Inc. stock a top pick in earnings seasonJuly 2025 Summary & Weekly Top Gainers Alerts - Улправда
CytomX Therapeutics, Inc. (CTMX) Stock Analysis: A 64.45% Potential Upside Amid Innovative Biotech Ventures - DirectorsTalk Interviews
Fed Meeting: Why CytomX Therapeutics Inc. stock could outperform in 2025Portfolio Profit Report & Intraday High Probability Alerts - Улправда
Why CytomX Therapeutics Inc. stock could outperform in 2025Weekly Earnings Recap & Momentum Based Trading Signals - Улправда
Is CytomX Therapeutics Inc. stock a safe investment in uncertain marketsWeekly Trading Summary & AI Powered Market Entry Strategies - ulpravda.ru
CytomX Therapeutics announces business update and company milestones for 2026 - marketscreener.com
Cytomx Therapeutics Announces Business Update And Company Milestones For 2026 - TradingView — Track All Markets
CytomX Therapeutics (CTMX) Reveals Plans for 2026 with Promising Clinical Developments - GuruFocus
CytomX Therapeutics Announces Business Update and Company Milestones for 2026 - manilatimes.net
New colorectal and melanoma drug trials expected to yield results in 2026 - Stock Titan
Piper Sandler and HC Wainwright stay bullish on CytomX (CTMX) - MSN
Why CytomX Therapeutics Inc. stock is recommended by analystsMarket Depth Overview & Low Entry Investment Growth - Улправда
Piper Sandler and H.C. Wainwright Stay Bullish on CytomX (CTMX) - Finviz
Is CytomX Therapeutics Inc a good long term investmentVolume Analysis Techniques & Free Trading Signals to Sharpen Your Edge - Early Times
What drives CytomX Therapeutics Inc 6C1 stock priceEmerging Market Stocks & High Return Stock Picks - earlytimes.in
What analysts say about CytomX Therapeutics Inc 6C1 stockEquity Performance Review & Collaborate and Win Together - earlytimes.in
CytomX Therapeutics (NASDAQ:CTMX) Hits New 1-Year HighHere's Why - MarketBeat
What drives CytomX Therapeutics Inc stock priceWeekly Market Snapshot & Investor Community Interactions - earlytimes.in
Chart Watch: Is CytomX Therapeutics Inc stock a safe investment in uncertain markets2025 Bull vs Bear & Verified Short-Term Trading Plans - moha.gov.vn
Will CytomX Therapeutics Inc. stock recover faster than peersChart Pattern Recognition & Exceptional Return Stocks - bollywoodhelpline.com
237,081 Shares in CytomX Therapeutics, Inc. $CTMX Acquired by Precision Wealth Strategies LLC - MarketBeat
Inspire Investing LLC Acquires Shares of 522,482 CytomX Therapeutics, Inc. $CTMX - MarketBeat
Cytomx Therapeutics Inc Stock (CTMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.38%
1.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):